Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

RAD001 Plus Carboplatin in Breast Cancer Patients

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: RAD001
Drug: Carboplatin

First Posted Date: 2010-05-21

Last Posted Date: 2014-04-09

Lead Sponsor: NYU Langone Health

Target Recruit Count: 25

Registration Number: NCT01127763

Locations: 🇺🇸
NYU Clinical Cancer Center, New York, New York, United States

A Study of MK-4827 in Combination With Standard Chemotherapy in Participants With Advanced Solid Tumors (MK-4827-008 AM1)

Phase 1

Terminated

Conditions: Cancer: Solid Tumors

Interventions: Drug: MK-4827
Drug: carboplatin
Drug: liposomal doxorubicin
Drug: paclitaxel

First Posted Date: 2010-04-26

Last Posted Date: 2016-05-05

Lead Sponsor: Tesaro, Inc.

Target Recruit Count: 12

Registration Number: NCT01110603

Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Biological: Bevacizumab
Drug: Pemetrexed Disodium Heptahydrate

First Posted Date: 2010-04-21

Last Posted Date: 2023-07-07

Lead Sponsor: ECOG-ACRIN Cancer Research Group

Target Recruit Count: 1516

Registration Number: NCT01107626

Locations: 🇺🇸
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Frankford Hospital Cancer Center - Torresdale Campus, Philadelphia, Pennsylvania, United States
🇺🇸
Albert Einstein Cancer Center, Philadelphia, Pennsylvania, United States

and more 430 locations

A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)

Phase 1

Completed

Conditions: NSCLC
Solid Tumors

Interventions: Drug: YM155
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-04-09

Last Posted Date: 2015-10-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT01100931

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer

Phase 2

Conditions: Endometrial Cancer

First Posted Date: 2010-04-08

Last Posted Date: 2013-08-07

Lead Sponsor: Medical University Innsbruck

Target Recruit Count: 39

Registration Number: NCT01100359

Locations: 🇦🇹
Innsbruck Universitaetsklinik, Innsbruck, Austria

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Phase 2

Completed

Conditions: Fallopian Tube Transitional Cell Carcinoma
FIGO Stage III Ovarian Cancer
FIGO Stage IIIA1 Ovarian Cancer
FIGO Stage IVB Ovarian Cancer
Ovarian Serous Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma
FIGO Stage IIIA1(i) Ovarian Cancer
FIGO Stage IIIA1(ii) Ovarian Cancer
FIGO Stage IIIC Ovarian Cancer
Ovarian Seromucinous Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-04-02

Last Posted Date: 2022-10-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01097746

Locations: 🇺🇸
MD Anderson Regional Care Center-Sugar Land, Sugar Land, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson Regional Care Center-Katy, Houston, Texas, United States

and more 2 locations

First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer

Phase 2

Conditions: Chemotherapeutic Agent Toxicity
Fatigue
Lung Cancer
Musculoskeletal Complications

First Posted Date: 2010-04-01

Last Posted Date: 2011-08-08

Lead Sponsor: Wales Cancer Trials Unit

Target Recruit Count: 52

Registration Number: NCT01097317

Locations: 🇬🇧
Nottingham City Hospital, Nottingham, England, United Kingdom

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Biological: Filgrastim
Drug: Ifosfamide
Procedure: Leukapheresis
Drug: Plerixafor
Biological: Rituximab

First Posted Date: 2010-04-01

Last Posted Date: 2018-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01097057

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Phase 3

Active, not recruiting

Conditions: Clear Cell Ependymoma
Papillary Ependymoma
Anaplastic Ependymoma
Cellular Ependymoma
Ependymoma
Brain Ependymoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Other: Clinical Observation
Drug: Cyclophosphamide
Drug: Cisplatin
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mesna
Drug: Vincristine

First Posted Date: 2010-03-31

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 479

Registration Number: NCT01096368

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
University of Illinois, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

and more 206 locations

Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of Oropharynx

Interventions: Radiation: IMRT
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2010-03-17

Last Posted Date: 2022-11-08

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 60

Registration Number: NCT01088802

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy